title: Long-term treatment of obese Zucker rats with LY255582 and other appetite suppressants.
abstract: LY255582, administered subcutaneously, decreased food intake and body weight gain of fed obese Zucker rats during the entire 30-day period of treatment. No tolerance to these biologic effects of LY255582 could be demonstrated. d-Amphetamine and naltrexone, administered subcutaneously, and d,l-fenfluramine and salbutamol, administered orally, decreased food intake for no more than 6 to 12 days, in contrast to the long-lasting effects of LY255582. Salbutamol suppressed the appetite of obese rats for 3-4 days only. After an additional 12 days of treatment, weight gain decreased significantly accompanied by no appetite suppression. Thus, there is a difference in the duration of action of the opioid antagonist, LY255582, when compared to amphetamine, fenfluramine, naltrexone, and salbutamol, on food intake and body weight gain of obese rats.
authors.affiliation: Diabetes Research, Lilly Research Laboratories, Indianapolis, IN 46825.
authors.forename: W N
authors.initials: WN
authors.lastname: Shaw
mesh_terms: D000420:Albuterol / Q000494:pharmacology; D000818:Animals; D001067:Appetite Depressants / Q000494:pharmacology*; D003510:Cyclohexanes / Q000494:pharmacology*; D003913:Dextroamphetamine / Q000494:pharmacology; D004361:Drug Tolerance; D004435:Eating / Q000187:drug effects*; D004723:Endorphins / Q000037:antagonists & inhibitors*; D005260:Female; D005277:Fenfluramine / Q000494:pharmacology; D007279:Injections, Subcutaneous; D008297:Male; D009271:Naltrexone / Q000494:pharmacology; D009765:Obesity / Q000523:psychology*; D010880:Piperidines / Q000494:pharmacology*; D051381:Rats; D011924:Rats, Zucker; D015430:Weight Gain / Q000187:drug effects
chemical_list: D001067:Appetite Depressants; D003510:Cyclohexanes; D004723:Endorphins; D010880:Piperidines; C070736:LY 243670; D005277:Fenfluramine; D009271:Naltrexone; D000420:Albuterol; D003913:Dextroamphetamine